' Background^ Recently, we have shown that dexrazoxane (ICRF-187) is an effective antidote against accidental extravasation of anthracyclines. Thus, it inhibits the lesions induced by subcutaneous (s.c.) daunorubicin, idarubicin, and doxorubicin in mice and has proven to be successful clinically as well. Dexrazoxane is a potent metal ion chelator as well as being a catalytic inhibitor of DNA topoisomerase II. However, the mechanism behind the protection against anthracycline extravasation is not known.
Introduction
Accidental extravasation of anthracyclines is a dreadful complication to the treatment of patients with cancer. Once extravasated, these DNA topoisomerase II propagate acute pain and progressive, long lasting severe necrosis [1, 2] . The mechanism behind the devastating soft tissue lesions induced by the anthracyclines is not understood. One often proposed explanation relates to sitespecific free radical damage, which progresses due to local diffusion of drug-DNA complexes into adjacent tissue. Formation of noxious free radicals inducing lipid peroxidation is also thought to be responsible for the dose dependent cardiotoxicity, which is a common feature shared by several of the clinically useful anthracyclines [3] [4] [5] . However, despite much effort no specific experimental antidotes to extravasation necrosis have gained access to the clinic. Until now, the sole effective treatment has therefore been extensive surgical debridement.
We have recently demonstrated that dexrazoxane is a highly effective antidote against anthracycline induced soft tissue lesions in mice. Thus, the frequency and sizes of lesions induced by s.c. anthracyclines such as daunorubicin, idarubicin, and doxorubicin is significantly reduced by a single systemic treatment with dexrazoxane.
Moreover, dexrazoxane has no effect on lesions induced by s.c. hydrogen peroxide [6] . Dexrazoxane (ICRF-187) is commercially available and licensed in many parts of the world for cardioprotection against doxorubicininduced cardiomyopathy. It is the water-soluble enantiomer of the racemic compound razoxane (ICRF-159) and penetrates readily into cells. Upon full intracellular hydrolysis it forms ADR-925, which is a strong chelator of iron and other metal ions [7] . Dexrazoxane is also a catalytic inhibitor of DNA topoisomerase II capable of blocking the action of topoisomerase II poisons in vitro [8] [9] [10] . Moreover, in animal models we have shown that exploiting the antagonism between dexrazoxane and topoisomerase II poisons, such as teniposide and etoposide, actually is a feasible way of directing chemotherapy to a body compartment, e.g., the brain [11, 12] . Accordingly, there are at least two known possible modes of interaction between the topoisomerase II poisons such as the anthracyclines doxorubicin and daunorubicin, and dexrazoxane: On one hand the catalytic cycle of topoisomerase II and on the other hand metal ion related oxidative stress pathways.
In order to explore the mechanism whereby dexrazoxane protects against the soft tissue damage of extravasated anthracyclines, we here compare the effect of systemically administered dexrazoxane with that of seven other adjuvants. These include other catalytic inhibitors of topoisomerase II (aclarubicin, merbarone), free radical scavengers (N-acetylcysteine and alfatocoferol), iron chelators (EDTA, ADR-925), and the broadly acting cytoprotective compound amifostine. To mimic a clinical extravasation accident as closely as possible, we use s.c. infiltrations of anthracyclines. To bypass the possibility of inefficiently low local tissue concentrations of the adjuvant drugs, we also investigate the effect of intralesional treatment with several of the adjuvants. Furthermore, an attempt to improve the efficacy of a single systemic administration of dexrazoxane is tested by administering dexrazoxane as triple-treatment in a lower dose. Finally, as it is often clinical practice to apply ice packs topically on the area of extravasation, the influence of concomitant or sole treatment with topical ice is tested as well.
Materials and methods
Individually marked female B6D2FI (M&B, Ry, Denmark) weighing 19-21 g were caged in groups of five or nine in a temperature and light controlled environment with act libitum access to food and water. The pre-e.xperimental acclimatization period was one to two weeks. Animal handling and daily observation was carried out according to animal welfare guidelines [13, 14] , All mice were anaesthetized with a standard solution containing one part fentanyl-fluanisone, one part midazolam, and two parts isotonic saline in an i.p. dose of 0.1 ml/10 g according to [15] and their backs were shaved with an electrical hair clipper.
Anthracyclines were injected s.c. with a 50 ul fixed-volume syringe Hamilton"'' syringe (Bonaduz AG, Bonaduz, Switzerland) and a 27G x 3/4" needle one centimetre cranially from the root of the tail after grabbing the dorsal skin. The concentrations of daunorubicin and doxorubicin were 3 mg/kg corresponding to approximately one fifth to one sixth of the LD10 for i.v. injection in this mouse strain. Systemic adjuvants were administered i.p. in volumes of 0.2 ml immediately after the s.c. injection of anthracycline, and where indicated also after three and six hours. Based on previous experiments [6] , the dose of dexrazoxane in triple-treatment was 62.5 mg/kg. EDTA and ADR-925 were administered in doses similar to dexrazoxane. Aclarubicin and alfa-tocoferol were tolerated in doses up to 20 mg/kg and 125 mg/kg, respectively, and N-acetylcysteine reached 1000 mg/kg. Due to limited availability, merbarone and amifostine were administered according to generally used experiment doses in mice, i.e., 100 and 200 mg/kg, respectively. Intralesional adjuvants were injected in volumes of 50 ul directly into the anthracycline-papule through a separate puncture immediately after the anthracycline. Intralesional doses were one fourth or one fifth (dexrazoxane) of the systemic doses. At these doses none of the drugs created lesions themselves (data not shown). Ice packs containing a mixture of crushed ice and water were placed over the caudal part of the dorsum on the anaesthetized mice immediately after s.c. injection of anthracycline for a period of 30 minutes. The icecovered area was approximately four times that of the s.c. infiltrated area. Due to anaesthesia induced hypothermia, thirty minutes was considered the longest tolerable cooling time.
Injection sites were observed daily. A wound was defined as loss of hair and dermal disruption of at least 2 mm 2 . Healing was defined as complete regrowth of hair in a wound area. The observation period ended, when all lesions had healed. 
Data handling and statistical methods
Sizes of lesions were measured every two days with a ruler. The wound areas were calculated from the product of the two longest perpendicular diameters. For each mouse, the wound area in mm 2 was plotted against time in days. Similarly, the mean area of wounds in each study group was calculated and plotted against time, and the area under the ulceration curve (AUC) was calculated. The mean AUC's were compared using the Mann-Whitney's nonparametric test. Where appropriate, the time to occurrence, duration, and frequency of wounds were recorded and compared using the Fischer's exact two-sided /-test. Student-Newman-Keul's test for comparison of means was used for analysis of inter experimental variations of the mean AUC in controls.
Results
Five of three hundred thirty-four mice (1%) died during anaesthesia, three of which were treated with merbarone 100 mg/kg. We observed no wound infections in the 329 evaluable mice, and all lesions healed within the observation period. None of the mice altered behaviour or experienced extensive weight loss as a sign of poor thriving. Table 1 provides detailed information of the recorded data, including the frequency of wounds, time to occurrence of wounds, duration of wounds, and area under the ulceration curve.
The inter experimental variation of the mean areas under the ulceration curve in the six control groups, i.e., daunorubicin s.c. + saline i.p., was not statistically significant (P -0.9277; mean area 1292 mm 2 x days; range 1180-1444 mm 2 x days) ( Figure 1 ). Hence, these data are cumulated in Table 1 . Forty-nine of fifty mice developed ulcers (98%) with a mean duration of 25.2 days (median 26 days, range 15-30 days). The two control groups in mice receiving s.c. doxorubicin are cumulated as well. Twelve of fourteen mice (86%) developed wounds after s.c. doxorubicin with a mean duration of 22.8 days (median 22.5, range 20-27 days).
Systemic triple-treatment with dexrazoxane completely prevents lesions due to s. c. daunorubicin or doxorubicin in mice
In mice receiving s.c. daunorubicin (/? = 27) and doxorubicin (n = 18), adjuvant systemic triple-treatment with dexrazoxane immediately after, three hours after, and Intralesional treatment with low-close dexrazoxane is six hours after the anthracycline completely prevented effective wounds (Figures 2 and 3) . Compared to the incidences of wounds in the control groups, this level of protection The i.l. saline control did not have any impact on the is obviously highly significant. frequency, sizes, or duration of lesions after s.c. dauno- rubicin, thus indicating lack of protection by mere dilution (Figure 4) . Compared to i.l. saline, i.l. dexrazoxane in a dose of 50 mg/kg reduced the area under the ulceration curve by 91% {P < 0.0001). The mean time to wounds was delayed by 5.5 days {P = 0.03), and the mean duration of wounds was reduced by 50% (P = 0.003). In contrast, neither i.l. EDTA (50 mg/kg), ADR-925 (50 mg/kg), nor N-acetylcysteine (200 mg/kg) had any impact on these parameters.
Topical cooling has no effect on the frequency or areas of wounds induced by s. c. daunorubicin nor does it reduce the efficacy of dexrazoxane treatment
Thirty minutes of local application of ice water did not change the frequency, sizes or duration of wounds compared to those induced by s.c. daunorubicin in the control group. No wounds developed when local cooling was combined with systemic dexrazoxane scheduled as triple-dosage over a six-hour period.
Adjuvant treatment with N-acetylcysteine, alfa-tocoferol, EDTA, amifostine, merbarone, ADR-925, and aclarubicin are ineffective in this model
A single i.p. treatment with N-acetylcysteine, alfa-tocoferol, EDTA, amifostine, merbarone, and aclarubicin had no impact on the appearance of daunorubicin-induced wound formation (Figure 2) . Moreover, changing the systemic treatment with EDTA and ADR-925 to a triple-dosage was ineffective as well. Finally, merbarone demonstrated no effect against wounds after s.c. doxorubicin ( Figure 3 ).
Discussion
Clearly, the most effective way of avoiding the devastating effects of extravasated vesicant drugs such as the anthracyclines is prevention. Accordingly, infusions of anthracyclines are handled with great precaution. However, accidents do unfortunately occur and will continue to do so with the broad use of anthracycline-containing therapy, mainly against the leukaemias, sarcomas, lymphomas, lung cancer, and breast cancer [16] . The availability of an effective antidote is therefore warranted. Our previous studies have identified dexrazoxane as such an effective antidote that can easily be implemented for clinical use [6] . The present study convincingly confirms the efficacy of the drug to inhibit full skin necrosis after subcutaneous infiltration with anthracyclines. The protection is increased by systemic triple-treatment, and we also show that a significant protection can be achieved by acute intralesional administration of lowdose dexrazoxane. In addition, the uniformity of the frequency, sizes, and duration of wounds induced in the control groups after both daunorubicin and doxorubicin ( Figure 1 ) is reassuring for this subcutaneous model as a tool for investigating the effects of possible antidotes to extravasation injuries.
Amifostine (WR-2721) is an organic thiophosphate prodrug that is dephosphorylated by membrane-bound alkaline phosphatases to the active compound WR-1065. Amifostine is licensed in many countries as a chemoand radioprotective agent. Its mechanism of action probably relates to the scavenging of free radicals [17] . Cytoprotective in vitro and in vivo experiments with amifostine have mainly focused on platinum-based chemotherapy. With respect to anthracyclines, amifostine has demonstrated significant cytoprotection in vitro towards doxorubicin-toxicity in rat myocytes [18] . Recently, experimental data has been presented, that show no inhibition of skin ulceration after intradermal (i.d.) doxorubicin in rats receiving adjuvant treatment with systemic amifostine [19] . This correlates with our results in mice, where amifostine in the same dose-level (200 mg/kg) had no impact on the appearances of s.c. daunorubicin induced lesions.
The immediate physiological effect of topical cooling is vasoconstriction and pain relief. Cooling is proposed to reduce the toxicity of doxorubicin by inducing structural changes in the cell membrane at temperatures below 20 °C, rather than leading to decreased intracellular drug concentrations [20] . Moreover, local cooling has experimentally been shown to reduce i.d. doxorubicin induced ulcers in mice [21] and pigs [22] but not daunorubicin induced lesions [23] . In our study, thirty minutes of cooling with iced water did not alter the wound sizes or frequency of wounds due to s.c. daunorubicin. Moreover, local cooling did not decrease the protection exerted by systemic dexrazoxane. Thus, the demonstrated lack of interference leads us to conclude that local cooling plus dexrazoxane can be used concomitantly.
Dexrazoxane probably protects against chronic doxorubicin-induced cardiomyopathy by intracellular binding of its one ring-opened or fully hydrolysed product (ADR-925) to doxorubicin-iron complexes or free iron, thereby preventing site-specific damage resulting from formation of superhydroxide radicals [24] . However, in the present experiments ADR-925 did not protect against anthracycline induced s.c. lesions, neither when it was administered intralesionally nor systemically in maximal tolerated doses. EDTA, which chemically is closely related to ADR-925 and dexrazoxane, also had no effect on the sizes, frequency, or duration of the daunorubicininduced lesions. In contrast to the nonpolar dexrazoxane, EDTA and ADR-925 are polar molecules, that are unlikely to cross the cell membrane [25] . Hence, our results indicate that extracellular free iron does not play a main role in the pathophysiological mechanism leading to anthracycline induced subdermal lesions.
To ensure a sufficiently high local drug concentration for anti-oxidant activity, treatment with N-acetylcysteine and alfa-tocoferol was carried out in two ways, i.e., systemically and intralesionally. In both schedules, we recorded no inhibition of daunorubicin-induced wounds. The lack of effect in this and other studies [26] [27] [28] indicates that dexrazoxane does not protect against the lesions after s.c. anthracyclines by this mechanism. This view is further supported by our previous findings that DEX had no effect on wound size or duration after s.c. hydrogen peroxide [6] . Aclarubicin and merbarone are catalytic inhibitors of topoisomerase II [29, 30] . Like dexrazoxane, they interact with the enzyme without stabilizing the cleavable complex formation, as opposed to, e.g., doxorubicin and etoposide [31] . Preclinical in vivo studies have shown that aclarubicin reduces the antineoplastic efficacy of the topoisomerase II poison etoposide. Thus, in a histological analysis it was shown that etoposide-induced apoptosis in the intestinal crypt cells was inhibited by the co-treatment with aclarubicin [32] . However, the present study demonstrates no protection against daunorubicin-induced subdermal lesions by systemic aclarubicin and merbarone. This clearly indicates that, if the protection is related to catalytic inhibition of topoisomerase II, it is restricted to the closed clamp formation of the enzyme induced by dexrazoxane. Attempts to induce reproducible wounds with aclarubicin and etoposide failed even in s.c. doses up to as high as 8 mg/kg and 30 mg/kg, respectively (data not shown). Consequently, we have not been able to study the effect of dexrazoxane on the appearance of such lesions.
According to these experiments, dexrazoxane is an extremely potent and specific inhibitor of wounds induced by anthracyclines such as daunorubicin and doxorubicin. However, our in vivo studies on mice have not defined the precise mechanism through which the protection is achieved.
